Tech Company Inital Public Offerings

Athira Pharma IPO

Headquartered in Seattle, Athira Pharma is now a public company.

Transaction Overview

Company Name
Announced On
Transaction Type
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows:approximately $75.0 million to fund the clinical development of ATH-1017 including the LIFT-AD trial and the ACT-AD P300 Phase 2 trial for the treatment of mild-to-moderate Alzheimer's disease;approximately $20.0 million to fund our planned Phase 2 trial of ATH-1017 for the treatment of Parkinson's disease dementia;approximately $30.0 million to fund our IND-enabling studies of ATH-1019 for the treatment of neuropsychiatric indications and ATH-1018 for the treatment of neuropathy; andthe remainder for our other research and development activities, as well as for working capital and other general corporate purposes.

Company Information

Company Status
Mailing Address
4000 Mason Rd. 300 Box 352141
Seattle, WA 98195
Email Address
Athira Pharma (Nasdaq: ATHA) is a drug development company striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. Our innovative approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function.
Athira Pharma LinkedIn Company Profile
Social Media
Athira Pharma Company Twitter Account
Company News
Athira Pharma News
Athira Pharma on Facebook
Athira Pharma on YouTube

Management Team

Email & Social
Chief Executive Officer
Leen Kawas
  Leen Kawas LinkedIn Profile  Leen Kawas Twitter Account  Leen Kawas News  Leen Kawas on Facebook
Chief Financial Officer
Glenna Mileson
  Glenna Mileson LinkedIn Profile  Glenna Mileson Twitter Account  Glenna Mileson News  Glenna Mileson on Facebook
Chief Operating Officer
Mark Litton
  Mark Litton LinkedIn Profile  Mark Litton Twitter Account  Mark Litton News  Mark Litton on Facebook
VP - Bus. Development
Josh Pan
  Josh Pan LinkedIn Profile  Josh Pan Twitter Account  Josh Pan News  Josh Pan on Facebook
VP - General Counsel
Christina Thomson
  Christina Thomson LinkedIn Profile  Christina Thomson Twitter Account  Christina Thomson News  Christina Thomson on Facebook
VP - R & D
Xue Hua
  Xue Hua LinkedIn Profile  Xue Hua Twitter Account  Xue Hua News  Xue Hua on Facebook



Browse more venture capital transactions:

Prev: 9/17/2020: Sun Genomics venture capital transaction
Next: 9/18/2020: Palleon Pharmaceuticals venture capital transaction


Share this article


About Our Venture Capital Transactions Database

We do our best to document every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The information comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary